Cingulate Inc. (CINGW)
0.04
-0.02 (-33.11%)
At close: Apr 03, 2025, 3:05 PM
0.04
0.00%
After-hours: Apr 03, 2025, 04:00 PM EDT
Company Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders.
The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders.
It also focuses on developing CTx-2103 for the treatment of anxiety disorders.
The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
Cingulate Inc.

Country | United States |
IPO Date | n/a |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13 |
CEO | Dr. Raul R. Silva M.D. |
Contact Details
Address: 1901 West 47th Place Kansas City, Kansas United States | |
Website | https://www.cingulate.com |
Stock Details
Ticker Symbol | CINGW |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001862150 |
CUSIP Number | 17248W113 |
ISIN Number | US17248W1137 |
Employer ID | 86-3825535 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Raul R. Silva M.D. | Co-Founder, Executive Vice President & Chief Science Officer |
Thomas Dalton | Vice President of Investor & Public Relations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2025 | 10-K | Annual Report |
Mar 26, 2025 | 8-K | Current Report |
Mar 04, 2025 | 8-K | Current Report |
Feb 20, 2025 | 4 | Filing |
Feb 20, 2025 | 4 | Filing |
Feb 20, 2025 | 4 | Filing |
Feb 20, 2025 | 4 | Filing |
Feb 20, 2025 | 4 | Filing |
Feb 03, 2025 | 8-K | Current Report |
Jan 24, 2025 | 8-K | Current Report |